Celltrion
068270.KS
#747
Rank
HK$210.80 B
Marketcap
HK$1,018
Share price
0.72%
Change (1 day)
8.50%
Change (1 year)
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.

Revenue for Celltrion (068270.KS)

Revenue in 2024 (TTM): HK$15.44 Billion

According to Celltrion 's latest financial reports the company's current revenue (TTM ) is HK$15.35 Billion. In 2023 the company made a revenue of HK$12.88 Billion a decrease over the revenue in the year 2022 that were of HK$13.70 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Celltrion from 2008 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) HK$15.44 B19.82%
2023 HK$12.88 B-5.94%
2022 HK$13.70 B6.71%
2021 HK$12.83 B4.06%
2020 HK$12.33 B63.36%
2019 HK$7.55 B8.02%
2018 HK$6.99 B5.2%
2017 HK$6.64 B47.36%
2016 HK$4.51 B11.14%
2015 HK$4.05 B16.45%
2014 HK$3.48 B117.16%
2013 HK$1.60 B-35.52%
2012 HK$2.48 B
2010 HK$1.22 B35.1%
2009 HK$0.90 B62.41%
2008 HK$0.55 B